Items where authors include "Drayson, M."

Article

Wong, K., Pitcher, D., Braddon, F. et al. (299 more authors) (2024) Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort. Kidney International Reports, 9 (7). pp. 2067-2083. ISSN 2468-0249

Wong, K., Pitcher, D., Braddon, F. et al. (299 more authors) (2024) Description and cross-sectional analyses of 25,880 adults and children in the UK National Registry of rare kidney diseases cohort. Kidney International Reports, 9 (7). pp. 2067-2083. ISSN 2468-0249

Wong, K., Pitcher, D., Braddon, F. et al. (294 more authors) (2024) Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. The Lancet, 403 (10433). pp. 1279-1289. ISSN 0140-6736

Wong, K., Pitcher, D., Braddon, F. et al. (294 more authors) (2024) Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. The Lancet, 403 (10433). pp. 1279-1289. ISSN 0140-6736

Agarwal, G., Moore, S., Sadler, R. et al. (21 more authors) (2024) Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma. Haematologica. ISSN 0390-6078

Twumasi, C. orcid.org/0000-0001-6817-8356, Moore, S. orcid.org/0000-0003-1380-1934, Sadler, R. orcid.org/0000-0003-2250-670X et al. (20 more authors) (2023) Determinants of durable humoral and T cell immunity in myeloma patients following <scp>COVID</scp>‐19 vaccination. European Journal of Haematology. ISSN 0902-4441

Proceedings Paper

Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.

Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.

Reed, M., Cairns, D.A. orcid.org/0000-0002-2338-0179, Pawlyn, C. et al. (13 more authors) (2023) The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial. In: Blood. 65th ASH Annual Meeting and Exposition, 09-12 Dec 2023, San Diego, USA. American Society of Hematology , pp. 3366-3368.

Cook, G., Ashcroft, A.J., Senior, E.R. et al. (16 more authors) (2023) Ixazomib-based consolidation and maintenance prolongs progression-free survival after salvage autologous stem cell transplantation (sASCT): Results from interim analysis of UK-MRA myeloma XII (ACCoRD). In: Blood. 65th ASH Annual Meeting, 09-12 Dec 2023, San Diego, California, USA. American Society of Hematology , p. 783.

Jiang, Y., Down, J., Raffles, S. et al. (6 more authors) (2018) Targeting free light chain (FLC) secretion and the unfolded protein response in myeloma cells using VaN, a combination of repurposed drugs. In: Experimental Hematology. 47th Annual Scientific Meeting of the ISEH - International Society for Experimental Hematology, 23-26 Aug 2018, Los Angeles, USA. Elsevier , S74-S75.